Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

02 May 2003 : Case report  

Use of PARP inhibitors to counteract the side effects of cytotoxic drugs

B. Sumegi, P. Deres

Med Sci Monit 2003; 9(1): 65- :: ID: 15204


Many antitumor drugs (doxorubicin (DOX), cisplatin (CisP), and AZT) induce oxidative stress in several tissues, which can contribute to their side effects [1–3]. Oxidative stress can trigger DNA damage and poly(ADP-ribose) polymerase (PARP) activation, which may contribute to an important pathway of cell dysfunction and tissue injury under the conditions associated with oxidative insult [4]. Oxidative injury is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), in the cardiotoxicity of AZT and in the nephrotoxicity caused by cisplatin. Thus, we and others hypothesized that the activation of PARP may contribute to the antitumor drug-induced cardiotoxicity and cisplatin-induced nephrotoxicity. DOX administration in PARP-1+/+ mice depressed left ventricular performance, while the heart function of PARP-1–/– ones and PARP-1+/+ mice treated with PJ34 (1) or HO-3089 (experimental PARP inhibitors) was deteriorated only to a smaller extent. Our data showed that PARP inhibitors activated cardiac Akt and GSK-3b, which may have contributed to their protective effect. Cisplatin-induced kidney dysfunction was prevented by another PARP inhibitor, BGP-15. The cisplatin-caused edema formation was reversed as showed by MRI analysis. High-energy phosphate intermediate levels were reestablished by BGP-15 treatment demonstrated in vivo by localized NMR spectroscopy, which was correlated with the diminished ADP-ribosylation in BGP-15-treated mice [3]. However, the anti-cytostatic effect of cisplatin was not compromised. These data indicate that PARP inhibitors may be applied in combination with cytostatic drugs and their side effects in the heart and kidney can be attenuated without compromising their antitumor efficacy. References: 1.Pacher P, Liaudet L, Bai P et al: Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther, 2002 Mar; 300(3): 862-7 2.Szabados E, Fisher MG, Toth K et al: Role of reactive oxygen species and poly-ADP-ribose polymerase in the development of AZT-induced cardiomyopathy in rat. Free Rad Biol & Med, 1999; 26: 309-317 3.Rabloczky G, Jaszlits L, Bárdos G, et al: Chemoprotective Effect Of A Novel PARP Inhibitor. Therapeutic utilities of PARP inhibitors, 2002; 223-228 4.Halmosi R, Berente Z, Osz E et al: Effect of Poly (ADP-Ribose) Polymerase Inhibitors on the Ischemia-Reperfusion Induced Oxidative Cell Damage and Mitochondrial Metabolism in Langendorff Heart Perfusion System. Mol Pharmacol, 2001; 59: 1497-1505

Keywords: PARP, ADP-ribose, cancer, Doxorubicin, akt. Phosphorylation



01 December 2022 : Editorial  

Editorial: The World Health Organization (WHO) Fungal Priority Pathogens List in Response to Emerging Fungal Pathogens During the COVID-19 Pandemic

Dinah V. Parums
Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

DOI: 10.12659/MSM.939088

Med Sci Monit 2022; 28:e939088


29 November 2022 : Clinical Research  

Retrospective Study to Identify Risk Factors for Severe Disease and Mortality Using the Modified Early Warn...

Med Sci Monit In Press; DOI: 10.12659/MSM.938647  

24 November 2022 : Clinical Research  

A Prospective Questionnaire-Based Study to Evaluate Factors Affecting the Decision to Receive COVID-19 Vacc...

Med Sci Monit In Press; DOI: 10.12659/MSM.938665  

01 November 2022 : Clinical Research  

Questionnaire-Based Study of 81 Patients in Poland to Evaluate the Course of Inflammatory Bowel Disease and...

Med Sci Monit 2022; 28:e938243

In Press

02 Dec 2022 : Clinical Research  

Value of Early Laparoscopic Exploration for Primary Infertile Patients with Patent Fallopian Tubes Complica...

Med Sci Monit In Press; DOI: 10.12659/MSM.938637  

30 Nov 2022 : Clinical Research  

Retrospective Evaluation of Hematological and Clinical Factors Associated with 30-Day Mortality in 170 Pati...

Med Sci Monit In Press; DOI: 10.12659/MSM.938674  

29 Nov 2022 : Clinical Research  

Retrospective Study to Identify Risk Factors for Severe Disease and Mortality Using the Modified Early Warn...

Med Sci Monit In Press; DOI: 10.12659/MSM.938647  

28 Nov 2022 : Review article  

A Review of the Roles of Apelin and ELABELA Peptide Ligands in Cardiovascular Disease, Including Heart Fail...

Med Sci Monit In Press; DOI: 10.12659/MSM.938112  

Most Viewed Current Articles

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

01 Nov 2020 : Review article  

Long-Term Respiratory and Neurological Sequelae of COVID-19

DOI :10.12659/MSM.928996

Med Sci Monit 2020; 26:e928996

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750